AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Hormone therapy for age-related muscle degeneration

Summary

Progressive muscle wasting is prevalent among the aging population. To date, the only treatment for sarcopenia—age-related loss of muscle fitness and strength—is regulation of diet and exercise. The blood circulating levels of the multifunctional, osteoblast-derived hormone osteocalcin decline with age, and this is thought to have an effect on the decline in muscle function. This technology utilizes osteocalcin as a treatment for age-related muscle loss and other degenerative muscular disorders, as well as a therapy for general improvement of muscle function.

Technology Benefits

There are no FDA-approved therapies for muscle wastingImproves muscle’s ability to metabolize glucose, synthesize proteins, and oxidize fatty acidsPatent Information:Patent Pending (WO/2016/081728)Tech Ventures Reference: IR CU15011

Technology Application

Treatment for sarcopenia, or age-related muscle wastingTreatment for cachexia, or illness related muscle-wastingTreatment for diabetes-related muscle atrophyTreatment for muscle atrophy from diseases such as muscular dystrophy, ALS, Guillian-Barre Syndrome, Dejerine–Sottas syndrome, Charcot-Marie-Tooth syndrome, multiple sclerosis

Detailed Technology Description

None

Country/Region

USA

For more information, please click Here